These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23823855)

  • 1. Ramipril for treatment of intermittent claudication.
    Poredos P
    Vasa; 2013 Jul; 42(4):237-8. PubMed ID: 23823855
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.
    Ahimastos AA; Walker PJ; Askew C; Leicht A; Pappas E; Blombery P; Reid CM; Golledge J; Kingwell BA
    JAMA; 2013 Feb; 309(5):453-60. PubMed ID: 23385271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramipril improves walking times and quality of life in patients with stable intermittent claudication.
    Brittenden J
    Evid Based Med; 2014 Feb; 19(1):16. PubMed ID: 23842688
    [No Abstract]   [Full Text] [Related]  

  • 4. ACP Journal Club. Ramipril improved walking times and QOL in peripheral artery disease and intermittent claudication.
    Jaar BG
    Ann Intern Med; 2013 Jun; 158(12):JC7. PubMed ID: 23778931
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors for intermittent claudication associated with peripheral arterial disease.
    Hunter MR; Cahoon WD; Lowe DK
    Ann Pharmacother; 2013 Nov; 47(11):1552-7. PubMed ID: 24285767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.
    Shahin Y; Cockcroft JR; Chetter IC
    Br J Surg; 2013 Aug; 100(9):1154-63. PubMed ID: 23842829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PURLs: ramipril for claudication?
    Stephens LA; Rogers N; Stevermer JJ
    J Fam Pract; 2013 Oct; 62(10):579-80. PubMed ID: 24143348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Füessl HS
    MMW Fortschr Med; 2013 May; 155(10):34. PubMed ID: 23930415
    [No Abstract]   [Full Text] [Related]  

  • 9. Medications for improving walking performance in peripheral artery disease: still miles to go.
    McDermott MM
    JAMA; 2013 Feb; 309(5):487-8. PubMed ID: 23385276
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
    Kurklinsky AK; Levy M
    Vasc Med; 2013 Aug; 18(4):234-6. PubMed ID: 23867841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.
    Ahimastos AA; Latouche C; Natoli AK; Reddy-luthmoodoo M; Golledge J; Kingwell BA
    Circ Res; 2014 Mar; 114(7):1144-55. PubMed ID: 24397981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of the outcome of endovascular and noninvasive therapies in the treatment of intermittent claudication.
    Ahimastos AA; Pappas EP; Buttner PG; Walker PJ; Kingwell BA; Golledge J
    J Vasc Surg; 2011 Nov; 54(5):1511-21. PubMed ID: 21958561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease.
    Park SY; Pekas EJ; Headid RJ; Son WM; Wooden TK; Song J; Layec G; Yadav SK; Mishra PK; Pipinos II
    Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H456-H467. PubMed ID: 32706261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summaries for patients. Ramipril improves walking ability in patients with peripheral arterial disease.
    Ann Intern Med; 2006 May; 144(9):I24. PubMed ID: 16670129
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of sildenafil on maximum walking time in patients with arterial claudication: The ARTERIOFIL study.
    Omarjee L; Le Pabic E; Custaud MA; Fontaine C; Locher C; Renault A; Jaquinandi V; Azzola V; Barbeau-Terrier C; Laporte I; Ripoche M; Onillon Y; Chretien JM; Daniel V; Chao de la Barca JM; Homedan C; Reynier P; Abraham P; Mahé G
    Vascul Pharmacol; 2019; 118-119():106563. PubMed ID: 31152977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ramipril on renal function in patients with intermittent claudication.
    Hobbs SD; Claridge MW; Wilmink AB; Adam DJ; Thomas ME; Bradbury AW
    Vasc Health Risk Manag; 2008; 4(2):471-5. PubMed ID: 18561523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials.
    Shahin Y; Mazari F; Chetter I
    Int J Surg; 2011; 9(3):209-13. PubMed ID: 21195215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of including quality of life responses in models to predict walking performance of patients with intermittent claudication.
    Leicht AS; Crowther RG; Muller R; Golledge J
    Eur J Vasc Endovasc Surg; 2011 Apr; 41(4):511-7. PubMed ID: 21247784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Effects of Medication Use on Intermittent Claudication: A Network Meta-analysis.
    Ma B; Fan X; Liu P
    J Cardiovasc Pharmacol; 2021 Feb; 77(2):253-262. PubMed ID: 33235027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.
    Ahimastos AA; Lawler A; Reid CM; Blombery PA; Kingwell BA
    Ann Intern Med; 2006 May; 144(9):660-4. PubMed ID: 16670135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.